Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 2, 2005, Pages 182-190

  Brunner, Martin ^a   Langer, Oliver ^b   Sunder Plassmann, Raute ^b   Dobrozemsky, Georg ^b   Müller, Ulrich ^b   Wadsak, Wolfgang ^b   Krcal, Andreas ^b   Karch, Rudolf ^b   Mannhalter, Christine ^b   Dudczak, Robert ^b   Kletter, Kurt ^b   Steiner, Ilka ^b   Baumgartner, Christoph ^b   Müller, Markus ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CALCIUM CHANNEL BLOCKING AGENT; CARBON 11; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; GENE FUNCTION; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE DISTRIBUTION; VENOUS BLOOD; WILD TYPE;

ADULT; AREA UNDER CURVE; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DOUBLE-BLIND METHOD; GENES, MDR; HAPLOTYPES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 23444433388     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.04.011     Document Type: Article

References (41)

1. T. Gerloff Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution Naunyn Schmiedebergs Arch Pharmacol 369 2004 69 77
2. I. Ieiri, H. Takane, K. Otsubo The MDR1 (ABCB1) gene polymorphism and its clinical implications Clin Pharmacokinet 43 2004 553 576
3. M. Eichelbaum, M.F. Fromm, M. Schwab Clinical aspects of the MDR1 (ABCB1) gene polymorphism Ther Drug Monit 26 2004 180 185
4. C. Marzolini, E. Paus, T. Buclin, R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
5. M.M. Gottesman, I. Pastan, S.V. Ambudkar P-glycoprotein and multidrug resistance Curr Opin Genet Dev 6 1996 610 617
6. A.H. Schinkel P-glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Deliv Rev 36 1999 179 194
7. A.H. Schinkel The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers Adv Exp Med Biol 500 2001 365 372
8. T. Sakaeda, T. Nakamura, K. Okumura Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs Pharmacogenomics 4 2003 397 410
9. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502
10. J. Van Asperen, A.H. Schinkel, J.H. Beijnen, W.J. Nooijen, P. Borst, O. van Tellingen Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice J Natl Cancer Inst 88 1996 994 999
11. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, P. Borst Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 96 1995 1698 1705
12. N.H. Hendrikse, A.H. Schinkel, E.G. de Vries, E. Fluks, W.T. Van der Graaf, A.T. Willemsen Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography Br J Pharmacol 124 1998 1413 1418
13. F. Zimprich, R. Sunder-Plassmann, E. Stogmann, A. Gleiss, A. Dal-Bianco, A. Zimprich Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy Neurology 63 2004 1087 1089
14. A. Siddiqui, R. Kerb, M.E. Weale, U. Brinkmann, A. Smith, D.B. Goldstein Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N Engl J Med 348 2003 1442 1448
15. S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, U. Brinkmann MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine Br J Clin Pharmacol 53 2002 526 534
16. T. Sakaeda, T. Nakamura, M. Horinouchi, M. Kakumoto, N. Ohmoto, T. Sakai MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects Pharm Res 18 2001 1400 1404
17. M.F. Fromm Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol Sci 25 2004 423 429
18. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
19. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 2002 584 594
20. B. Chowbay, S. Cumaraswamy, Y.B. Cheung, Q. Zhou, E.J. Lee Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients Pharmacogenetics 13 2003 89 95
21. N.H. Hendrikse, E.G. de Vries, L. Eriks-Fluks, W.T. van der Graaf, G.A. Hospers, A.T. Willemsen A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier Cancer Res 59 1999 2411 2416
22. P.H. Elsinga, N.H. Hendrikse, J. Bart, W. Vaalburg, A. van Waarde PET studies on P-glycoprotein function in the blood-brain barrier how it affects uptake and binding of drugs within the CNS Curr Pharm Des 10 2004 1493 1503
23. M. Brunner, O. Langer, G. Dobrozemsky, U. Müller, M. Zeitlinger, M. Mitterhauser [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans Antimicrob Agents Chemother 48 2004 3850 3857
24. R. Sunder-Plassmann, S. Rieger, G. Endler, M. Brunner, M. Müller, C. Mannhalter Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR Clin Chem Lab Med 43 2005 192 194
25. 11C]verapamil Appl Radiat Isot 57 2002 505 507
26. 11C]methyl triflate Appl Radiat Isot 43 1992 1383 1385
27. 11C]methyl triflate Nucl Med Biol 26 1999 467 471
28. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
29. Y. Kurata, I. Ieiri, M. Kimura, T. Morita, S. Irie, A. Urae Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein Clin Pharmacol Ther 72 2002 209 219
30. N.H. Hendrikse, J. Bart, E.G. de Vries, H.J. Groen, W.T. van der Graaf, W. Vaalburg P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography J Clin Pharmacol 41 Suppl 2001 48S 54S
31. L. Sasongko, J.M. Link, M. Muzi, D.A. Mankoff, X. Yang, A.C. Collier Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography Clin Pharmacol Ther 77 2005 503 514
32. J. Bart, N.H. Hendrikse, T.A. Winette, W. van der Graaf, E. de Vries, W. Vaalburg P-glycoprotein function of the blood-brain barrier in humans can be measured with positron emission tomography [abstract] 2001 Proceedings of the Thirty-seventh American Society of Clinical Oncology Annual Meeting; May 12-15; San Francisco, Calif. Available from: URL: http://www.asco.org/ac/1,1003,_12- 002636-00_18-0010-00_19-00289,00.asp. Accessed April 20, 2005
33. D.L. Keefe, Y.G. Yee, R.E. Kates Verapamil protein binding in patients and in normal subjects Clin Pharmacol Ther 29 1981 21 26
34. C. Verstuyft, M. Schwab, E. Schaeffeler, R. Kerb, U. Brinkmann, P. Jaillon Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur J Clin Pharmacol 58 2003 809 812
35. J.E. Ros, L. Libbrecht, M. Geuken, P.L. Jansen, T.A. Roskams High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease J Pathol 200 2003 553 560
36. N.E. Vilaboa, A. Galan, A. Troyano, E. de Blas, P. Aller Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1) J Biol Chem 275 2000 24970 24976
37. Y. Lu, Y. Yan, X.F. Wang Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains Chin Med J (Engl) 117 2004 1682 1686
38. D.M. Tishler, K.I. Weinberg, D.R. Hinton, N. Barbaro, G.M. Annett, C. Raffel MDR1 gene expression in brain of patients with medically intractable epilepsy Epilepsia 36 1995 1 6
39. P. Borst, R. Evers, M. Kool, J. Wijnholds A family of drug transporters the multidrug resistance-associated proteins J Natl Cancer Inst 92 2000 1295 1302
40. C. Pauli-Magnus, J. Feiner, C. Brett, E. Lin, D.L. Kroetz No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects Clin Pharmacol Ther 74 2003 487 498
41. W.S. Putnam, J.M. Woo, Y. Huang, L.Z. Benet Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics J Clin Pharmacol 45 2005 411 421